PPARα agonist fenofibrate attenuates cardiac fibrosis, lipid accumulation, and inflammation by modulating TNF signaling, and its use has been linked to a reduced risk of HF-related hospitalization.607. The gene discussed is PPARA; the disease is hydrops fetalis.